Sebaceous Gland Diseases: Clinical Trials

590 completed, 108 unknown, 36 not yet recruiting, 34 recruiting. 216 Not applicable, 155 Phase 2, 144 Phase 3, 126 Phase 4, 107 Phase 1.

By phase and status

Phase	Trials	Status
Not applicable	216	Completed 125, Unknown 41, Not yet recruiting 13, Recruiting 12, Terminated 11, Withdrawn 9, Active not recruiting 5
Phase 2	155	Completed 111, Unknown 18, Not yet recruiting 7, Terminated 7, Active not recruiting 5, Recruiting 3, Withdrawn 3, Enrolling by invitation 1
Phase 3	144	Completed 117, Unknown 11, Recruiting 4, Active not recruiting 3, Not yet recruiting 3, Withdrawn 3, Terminated 2, Enrolling by invitation 1
Phase 4	126	Completed 99, Unknown 13, Terminated 4, Not yet recruiting 3, Recruiting 3, Active not recruiting 2, Withdrawn 2
Phase 1	107	Completed 90, Unknown 7, Recruiting 4, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2
Early Phase 1	17	Completed 8, Recruiting 4, Not yet recruiting 2, Active not recruiting 1, Terminated 1, Unknown 1

Follow Sebaceous Gland Diseases: new trials by email Literature Review of Sebaceous Gland Diseases trials Research Report on Sebaceous Gland Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Role of Akkermansia Muciniphila in Acne Vulgaris Akkermansia Muciniphila, Clostridium Beijerinckii, Anaerobutyricum Hallii, Clostridium Butyricum, Bifidobacterium Infantis Probiotic Capsule - Acne	Early Phase 1	Not yet recruiting	Medical University of South Carolina	34	2027-03-01	2026-05-12
Clascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne Clascoterone 1% cream, Clindamycin 1% lotion, Adapalene 0.1%/benzoyl peroxide 2.5% gel - Acne Vulgaris	Phase 4	Not yet recruiting	Allied Hospital Faisalabad	118	2026-11-01	2026-10-19
Safety of the Acne mRNA Vaccine in Adolescents 12 to 17 Years of Age With Moderate to Severe Acne Acne mRNA (messenger ribonucleic acid) vaccine, Placebo - Acne	Phase 2	Not yet recruiting	Sanofi	410	2026-10-30	2026-09-18
Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris Clascoterone 1% cream, Adapalene 0.1% cream - Acne Vulgaris	Not applicable	Recruiting	Pak Emirates Military Hospital	130	2026-10-08	2026-10-22
TRIDERM D.S. Crema Normalizzante for Neonatal Hyperseborrhea (Cradle Cap) and Associated Cutaneous Manifestations of Mild-to-Moderate Seborrheic Dermatitis in Children Aged 0 to 3 Years TRIDERM D.S. Crema Normalizzante - Cradle Cap, Seborrheic Dermatitis	Not applicable	Not yet recruiting	ICIM International S.r.l.	20	2026-10-01	2026-10-06
Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris B244, Vehicle - Acne Vulgaris	Phase 2	Not yet recruiting	AOBiome LLC	176	2026-10-01	2026-10-08
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) Denifanstat, Placebo - Acne Vulgaris	Phase 3	Recruiting	Sagimet Biosciences Inc.	800	2026-10-01	2026-10-29
Demodex Mites in Acne Patients and Herbal Extract Susceptibility Acne, Demodex Infestation		Not yet recruiting	Assiut University	80	2026-09-26	2026-09-28
Radiofrequency Treatment Versus Topical Therapy for Facial Acne Vulgaris Adapalene 0.1% and Benzoyl Peroxide 2.5% gel, Sequential Radiofrequency Treatment - Acne Vulgaris	Not applicable	Recruiting	Jeisys Medical Inc	60	2026-09-15	2026-09-04
Investigating the Efficacy of Oral Probiotics Versus Placebo in Pakistani Patients With Moderate Acne on Acne Lesion Count and Systemic Inflammation Probiotics, Placebo - Acne Vulgaris	Not applicable	Not yet recruiting	Foundation University Islamabad	64	2026-09-01	2026-04-20
A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology Flexible ePROM-guided Scheduling System, electronic patient reported outcome measures (ePROMs) - Chronic Dermatological Conditions, Eczema	Not applicable	Not yet recruiting	National University Hospital, Singapore	250	2026-09-01	2026-07-01
Evaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation Vinoperfect brightening serum - Post-inflammatory Hyperpigmentation, Post-acne Hyperpigmentation	Not applicable	Not yet recruiting	Weill Medical College of Cornell University	20	2026-09-01	2026-10-30
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis	Phase 3	Not yet recruiting	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	309	2026-08-24	2026-08-21
Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg), Placebo - Acne Vulgaris, Acne Vulgaris on the Face	Phase 3	Recruiting	Eurofarma Laboratorios S.A.	531	2026-08-24	2026-10-27
Comparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris Clascoterone Cream 1%, Adapalene 0,1% cgel - Acne Vulgaris	Early Phase 1	Not yet recruiting	Khyber Teaching Hospital	60	2026-08-15	2026-06-29
Prevalence of Polyendocrine Metabolic Ovarian Syndrome in Patients Diagnosed With Acne Vulgaris in Sohag University Hospital Polyendocrine Metabolic Ovarian Syndrome, Acne Vulgaris		Recruiting	Sohag University	90	2026-08-09	2026-09-16
Photodynamic Therapy With Topical Application of a Zn(II) Phthalocyanine (RLP068/Cl) and Red Light for the Treatment of Moderate-to-severe Acne Vulgaris Zn(II)-phthalocyanine gel - Acne	Not applicable	Not yet recruiting	Università degli Studi di Brescia	10	2026-08-01	2026-05-04
Clinical Observation of Skin Condition in Patients With Acne Vulgaris Using Ubiquinol, Pomegranate Peel Extract, Ceramide, and Salicylic Acid Emulsion Acne		Not yet recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	40	2026-07-20	2026-07-29
A Clinical Trial to Investigate the Efficacy and Safety of GenLabs' Social Renew on Improving Acne Symptoms and Skin Repair Among Healthy Adults Social Renew, Placebo - Acne	Not applicable	Not yet recruiting	GenCanna Acquisition Corp	150	2026-07-01	2026-06-30
Low-Dose Versus Conventional-Dose Oral Isotretinoin for Acne Vulgaris Isotretinoin - Acne Vulgaris	Phase 4	Not yet recruiting	Pakistan Institute of Medical Sciences	164	2026-07-01	2026-06-10

Showing 20 of 833. Sign in to see all of them.

Narrower conditions

Acne Vulgaris (779)  ·  Dermatitis, Seborrheic (56)  ·  Psoriasis (17)  ·  Cicatrix (16)  ·  Dermatitis, Atopic (14)  ·  Rosacea (14)  ·  Hyperpigmentation (12)  ·  Dermatitis (10)  ·  Eczema (10)  ·  Skin Diseases (10)  ·  Alopecia (9)  ·  Hidradenitis Suppurativa (8)  ·  Erythema (5)  ·  Facies (5)  ·  Hirsutism (5)

Broader conditions

Skin and Connective Tissue Diseases (833)  ·  Skin Diseases (823)  ·  Acneiform Eruptions (779)  ·  Skin Diseases, Eczematous (75)  ·  Dermatitis (70)  ·  Skin Diseases, Papulosquamous (70)  ·  Pathological Conditions, Signs and Symptoms (66)  ·  Pathologic Processes (44)  ·  Immune System Diseases (27)  ·  Infections (25)  ·  Signs and Symptoms (24)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23)  ·  Genetic Diseases, Inborn (20)  ·  Hypersensitivity (20)

Interventions

Gels (64)  ·  Adapalene (63)  ·  Benzoyl Peroxide (51)  ·  Clindamycin (36)  ·  Isotretinoin (30)  ·  Tretinoin (29)  ·  Doxycycline (23)  ·  Adapalene, Benzoyl Peroxide Drug Combination (21)  ·  Dapsone (19)  ·  Clascoterone (16)  ·  tazarotene (16)  ·  Minocycline (15)  ·  clindamycin phosphate (15)  ·  Salicylic Acid (13)  ·  berdazimer sodium (13)

Sponsors

Galderma R&D (45)  ·  Stiefel, a GSK Company (30)  ·  Bausch Health Americas, Inc. (27)  ·  Sun Pharmaceutical Industries, Inc. (22)  ·  Assiut University (18)  ·  Cosmetique Active International (13)  ·  GlaxoSmithKline (13)  ·  Novan, Inc. (13)  ·  Allergan (11)  ·  Pierre Fabre Dermo Cosmetique (11)  ·  Integrative Skin Science and Research (9)  ·  Sohag University (9)  ·  Almirall, S.A. (8)  ·  Bayer (8)  ·  University of California, Davis (8)

Countries

United States (388)  ·  Canada (61)  ·  China (38)  ·  Egypt (37)  ·  France (28)  ·  Poland (24)  ·  Germany (19)  ·  Brazil (17)  ·  Spain (17)  ·  Indonesia (16)  ·  Turkey (Türkiye) (14)  ·  Belize (12)  ·  Israel (12)  ·  Italy (12)  ·  Australia (11)

Top investigators

Anya Loncaric (13)  ·  Michael Graeber, MD (7)  ·  Natalie Yantovskiy (6)  ·  David Berk, MD (5)  ·  Joyce Rico, MD (5)  ·  Anya Loncaric, MS (4)  ·  Beth Zib (4)  ·  John J Voorhees, MD (4)  ·  Robert Bissonnette, MD (4)

Results publications

PMID 40377868, PMID 20684151, PMID 27518661, PMID 27847545, PMID 29380251, PMID 30500139, PMID 30500140, PMID 30500141, PMID 32320027, PMID 32886337, PMID 34607697, PMID 36745367, PMID 38724841, PMID 39141589, PMID 10951254, PMID 11488820, PMID 12095065, PMID 12243706, PMID 12553848, PMID 12839559, PMID 16247244, PMID 16575387, PMID 1699862, PMID 17314442, PMID 17616769, PMID 18249468, PMID 18394082, PMID 18472984, PMID 18532922, PMID 18720689, PMID 18827119, PMID 19075138, PMID 19376456, PMID 19439902, PMID 19746769, PMID 19911678, PMID 20213916, PMID 20214175, PMID 20404229, PMID 20677537, PMID 20981308, PMID 21108671, PMID 21143923, PMID 21288628, PMID 21572783, PMID 21880356, PMID 22168326, PMID 22253996, PMID 22341881, PMID 22678562

NIH funding

2023 (4), 2025 (3), 2016 (2), 2014 (1), 2017 (1), 2018 (1), 2019 (1), R01AR053542 (1), R01HD065029 (1), U01AR079752 (1), UM1CA186709 (1), UM1CA186716 (1)